We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
-0.63%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$150M
AUM Growth
-$19.5M
Cap. Flow
-$10.6M
Cap. Flow %
-7.05%
Top 10 Hldgs %
52.92%
Holding
99
New
9
Increased
16
Reduced
55
Closed
13

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$1.62M
2
LLY icon
Eli Lilly
LLY
+$1.28M
3
HCAT icon
Health Catalyst
HCAT
+$1.27M
4
PRVA icon
Privia Health
PRVA
+$1.03M
5
CLOV icon
Clover Health Investments
CLOV
+$983K

Top Sells

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$1.8M
2
ZBH icon
Zimmer Biomet
ZBH
+$1.46M
3
ICLR icon
Icon
ICLR
+$1.32M
4
EW icon
Edwards Lifesciences
EW
+$1.26M
5
OPCH icon
Option Care Health
OPCH
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
1
LENZ Therapeutics
LENZ
$158M
$28.2M 18.83%
977,245
– –
CTNM
2
Contineum Therapeutics
CTNM
$537M
$11.7M 7.83%
800,787
-100
-0% -$1.58K
LLY icon
3
Eli Lilly
LLY
$1.06T
$9.69M 6.46%
12,546
+1,550
+14% +$1.28M
UNH icon
4
UnitedHealth
UNH
$385B
$7.4M 4.94%
14,625
+1,500
+11% +$852K
GILD icon
5
Gilead Sciences
GILD
$162B
$4.74M 3.16%
51,310
-9,755
-16% -$878K
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.38B
$4.69M 3.13%
380,883
+51,370
+16% +$672K
ABBV icon
7
AbbVie
ABBV
$454B
$3.34M 2.23%
18,800
+3,000
+19% +$552K
JNJ icon
8
Johnson & Johnson
JNJ
$624B
$3.31M 2.21%
22,900
-3,000
-12% -$465K
AMGN icon
9
Amgen
AMGN
$201B
$3.27M 2.18%
12,550
+5,460
+77% +$1.62M
BSX icon
10
Boston Scientific
BSX
$64.8B
$2.91M 1.94%
32,526
-500
-2% -$44K
ABT icon
11
Abbott
ABT
$175B
$2.76M 1.84%
24,398
+5,000
+26% +$578K
BMY icon
12
Bristol-Myers Squibb
BMY
$126B
$2.49M 1.66%
44,000
-6,000
-12% -$335K
TMO icon
13
Thermo Fisher Scientific
TMO
$213B
$2.47M 1.65%
4,750
-500
-10% -$275K
MRK icon
14
Merck
MRK
$322B
$2.44M 1.63%
24,500
+500
+2% +$51.5K
REGN icon
15
Regeneron Pharmaceuticals
REGN
$68.3B
$2.42M 1.62%
3,400
– –
SYK icon
16
Stryker
SYK
$122B
$2.31M 1.54%
6,400
-1,050
-14% -$389K
BNTX icon
17
BioNTech
BNTX
$23.3B
$2.16M 1.44%
18,950
+5,795
+44% +$661K
MDT icon
18
Medtronic
MDT
$105B
$2.12M 1.41%
26,350
-3,000
-10% -$260K
ARGX icon
19
argenx
ARGX
$57.8B
$2.11M 1.41%
3,430
-567
-14% -$332K
PFE icon
20
Pfizer
PFE
$143B
$2.06M 1.38%
77,650
-37,000
-32% -$1M
BOLD
21
Boundless Bio
BOLD
$56.6M
$1.97M 1.31%
678,574
– –
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$35.9B
$1.95M 1.3%
8,300
-1,390
-14% -$366K
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.4B
$1.93M 1.29%
29,400
-7,470
-20% -$500K
DHR icon
24
Danaher
DHR
$135B
$1.67M 1.12%
7,275
+2,500
+52% +$614K
NBIX icon
25
Neurocrine Biosciences
NBIX
$17.5B
$1.61M 1.08%
11,800
-715
-6% -$88.4K
1
2 3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Sectoral Asset Management held 99 positions worth $150M, down 12% from $169M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sectoral Asset Management withdrew a net $10.6M in Q4 2024, closing 13 positions and reducing 55 holdings. Its most notable exit was IQVIA, an estimated $1.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Health Catalyst worth $1.13M.

  • Sectoral Asset Management's largest Q4 2024 buy was Health Catalyst: 160,000 shares worth $1.13M.
  • Sectoral Asset Management added most to Amgen in Q4 2024, an estimated $1.62M increase.
  • Sectoral Asset Management's biggest Q4 2024 reduction was Edwards Lifesciences, cutting an estimated $1.26M.
  • Sectoral Asset Management fully exited IQVIA in Q4 2024, selling an estimated $1.8M.
  • Sectoral Asset Management's ten largest holdings make up 53% of its $150M portfolio in Q4 2024.
  • Sectoral Asset Management opened 9 new positions and closed 13 in Q4 2024.
  • Sectoral Asset Management's portfolio value fell 12% quarter-over-quarter to $150M.

Based on Sectoral Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.